{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:54:17Z","timestamp":1794020057426,"version":"4.8.0"},"reference-count":273,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.autrev.2024.103693","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T12:51:19Z","timestamp":1732107079000},"page":"103693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally"],"prefix":"10.1016","volume":"24","author":[{"given":"Benjamin P.","family":"Trewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Brilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0005","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0010","first-page":"443","article-title":"Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein","volume":"130","author":"Linington","year":"1988","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458506072189","article-title":"Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations","volume":"13","author":"Pittock","year":"2007","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"14","key":"10.1016\/j.autrev.2024.103693_bb0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler J"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0050","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder&quest","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol: Neuroimmunol Neuroinflam"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1352458518823486","article-title":"Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis","volume":"26","author":"Rossor","year":"2020","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2024.103693_bb0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of multiple sclerosis: 2023 revision of the MENACTRIMS guidelines","volume":"83","author":"Yamout","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105093","article-title":"Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis","volume":"80","author":"Molazadeh","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0110","article-title":"Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: a study from the RelevarEM registry","volume":"9","author":"Contentti","year":"2023","journal-title":"Mult Scler J Exp, Transl Clin"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0115","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103693_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103884","article-title":"Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy","volume":"63","author":"Orlandi","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ncn3.12479","article-title":"Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore\u2014epidemiology and evolution of an emerging subspecialty","volume":"9","author":"Tan","year":"2021","journal-title":"Neurol Clin Neurosci"},{"issue":"4\u20135","key":"10.1016\/j.autrev.2024.103693_bb0130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/13524585231156736","article-title":"Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey","volume":"29","author":"Nakamura","year":"2023","journal-title":"Mult Scler J"},{"issue":"7","key":"10.1016\/j.autrev.2024.103693_bb0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2024.103693_bb0140","first-page":"160","article-title":"The epidemiology of myelin oligodendrocyte glycoprotein antibody associated disorders","volume":"25","author":"Flanagan","year":"2019","journal-title":"Mult Scler J"},{"issue":"Neurology 59 2002","key":"10.1016\/j.autrev.2024.103693_bb0145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000702","article-title":"HLA association in MOG-IgG\u2013 and AQP4-IgG\u2013related disorders of the CNS in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol - Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.autrev.2024.103693_bb0155","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong HLA association with MOG antibody disease in the UK population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105130","article-title":"Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"81","author":"Martin","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0165","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","author":"Virupakshaiah","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1474-4422(21)00247-7","article-title":"Clinical decision making in MOG antibody-associated disease","volume":"20","author":"Dale","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0175","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.autrev.2024.103693_bb0180","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/ene.13932","article-title":"Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity","volume":"26","author":"Ramanathan","year":"2019","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103693_bb0185","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/1352458519849511","article-title":"Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study","volume":"26","author":"Ciron","year":"2019","journal-title":"Mult Scler J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0190","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0195","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.26549","article-title":"Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"93","author":"Valencia-Sanchez","year":"2023","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0210","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0215","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody\u2013positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0220","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0230","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103044","article-title":"A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: a meta-analysis","volume":"53","author":"Bai","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0240","article-title":"Treatment of MOG-IgG associated disease in paediatric patients: a systematic review","volume":"56","author":"da Costa","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0245","article-title":"Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody\u2013associated disease: a systematic review and meta-analysis","volume":"14","author":"Lai","year":"2021","journal-title":"Ther Adv Neurol Diso"},{"key":"10.1016\/j.autrev.2024.103693_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103310","article-title":"Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder","volume":"56","author":"Thakolwiboon","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb0255","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/bjophthalmol-2020-317267","article-title":"Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review","volume":"105","author":"Vosoughi","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2024.103693_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102057","article-title":"Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis","volume":"42","author":"Shen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2018.09.011","article-title":"Retinal nerve fiber layer thickness in optic neuritis with MOG antibodies: a systematic review and meta-analysis","volume":"325","author":"Peng","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103118","article-title":"Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis","volume":"54","author":"Carandini","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"25","key":"10.1016\/j.autrev.2024.103693_bb0275","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0280","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","article-title":"Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis","volume":"183","author":"McLaughlin","year":"2009","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0285","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"issue":"21","key":"10.1016\/j.autrev.2024.103693_bb0290","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/WNL.0b013e3181e04096","article-title":"Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases","volume":"74","author":"Selter","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0295","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1352458510389220","article-title":"Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children","volume":"17","author":"Lalive","year":"2010","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0300","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2024.103693_bb0305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2014.03.001","article-title":"Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system","volume":"270","author":"Tanaka","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0310","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol: Neuroimmunol Neuroinflam"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0315","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0320","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.braindev.2015.02.006","article-title":"Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies","volume":"37","author":"Hino-Fukuyo","year":"2015","journal-title":"Brain Dev"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/01658107.2015.1072726","article-title":"Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis","volume":"39","author":"Matsuda","year":"2015","journal-title":"Neuro-ophthalmology"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0340","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1352458515591071","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications","volume":"22","author":"Cobo-Calvo","year":"2016","journal-title":"Mult Scler J"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0345","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurology - Neuroimmunol Neuroinflam"},{"issue":"12","key":"10.1016\/j.autrev.2024.103693_bb0350","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","article-title":"Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD","volume":"59","author":"Yan","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0355","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult Scler J"},{"issue":"7","key":"10.1016\/j.autrev.2024.103693_bb0360","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sepulveda","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0370","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0375","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0380","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0385","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0036-1583184","article-title":"Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination: clinical course, neuroimaging findings, and response to therapy","volume":"47","author":"Thulasirajah","year":"2016","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.autrev.2024.103693_bb0390","article-title":"Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India","volume":"2","author":"Pandit","year":"2016","journal-title":"Multiple Scler J Exp Transl Clin"},{"issue":"7","key":"10.1016\/j.autrev.2024.103693_bb0395","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458515614093","article-title":"The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-ab) in Thai patients","volume":"22","author":"Siritho","year":"2016","journal-title":"Mult Scler J"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0400","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1756285616655264","article-title":"Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders","volume":"9","author":"Martinez-Lapiscina","year":"2016","journal-title":"Ther Adv Neurol Diso"},{"issue":"14","key":"10.1016\/j.autrev.2024.103693_bb0405","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1177\/1352458517734070","article-title":"A population-based prospective study of optic neuritis","volume":"23","author":"Soelberg","year":"2017","journal-title":"Mult Scler J"},{"issue":"12","key":"10.1016\/j.autrev.2024.103693_bb0410","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0415","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103693_bb0420","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0425","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1590\/0004-282x20170121","article-title":"MOG-IgG associated optic neuritis is not multiple sclerosis","volume":"75","author":"Costa","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0430","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0435","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","article-title":"Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients","volume":"381","author":"Bouzar","year":"2017","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0440","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0445","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0455","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"\u201cLeukodystrophy-like\u201d phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb0460","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/ene.13753","article-title":"Acute idiopathic optic neuritis: not always benign","volume":"25","author":"Deschamps","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0465","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jns.2018.01.042","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures","volume":"387","author":"Gutman","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103693_bb0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.06.003","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody associated with gray matter predominant transverse myelitis mimicking acute flaccid myelitis: a presentation of two cases","volume":"86","author":"Wang","year":"2018","journal-title":"Pediatr Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb0475","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0480","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2018.03.003","article-title":"Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort","volume":"21","author":"Soelberg","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0485","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0490","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Brit J Ophthalmol"},{"issue":"21","key":"10.1016\/j.autrev.2024.103693_bb0495","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.autrev.2024.103693_bb0500","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2018.09.010","article-title":"Clinical utility of anti-MOG antibody testing in a Danish cohort","volume":"26","author":"Papp","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0505","first-page":"950","article-title":"Diagnostic implications of MOG\/AQP4 antibodies in recurrent optic neuritis","volume":"16","author":"Peng","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.autrev.2024.103693_bb0510","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0515","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0520","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2018.07.026","article-title":"Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?","volume":"25","author":"Papais-Alvarenga","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0525","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.msard.2017.12.018","article-title":"Magnetic resonance imaging findings at the first episode of acute optic neuritis","volume":"20","author":"Soelberg","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0530","article-title":"MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response","volume":"4","author":"Pandit","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0535","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","article-title":"MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein","volume":"265","author":"Baumann","year":"2018","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0540","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0545","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0550","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00415-018-8956-y","article-title":"Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation","volume":"265","author":"Lotan","year":"2018","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0555","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen3.12458","article-title":"Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study","volume":"9","author":"Holroyd","year":"2018","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb0560","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jneuroim.2018.09.010","article-title":"Recurrent optic neuritis - different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease","volume":"324","author":"Lotan","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","article-title":"Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders","volume":"26","author":"Konuskan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0570","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0575","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cen3.12459","article-title":"Three Japanese adult cases of brain lesions with anti-myelin oligodendrocyte glycoprotein antibodies lacking optic neuritis and myelitis","volume":"9","author":"Sawada","year":"2018","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb0580","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.msard.2019.07.004","article-title":"A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children","volume":"35","author":"Manguinao","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0585","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2019.03.009","article-title":"Acute disseminated encephalomyelitis (ADEM) and increased intracranial pressure associated with anti-myelin oligodendrocyte glycoprotein antibodies","volume":"99","author":"Narayan","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.msard.2018.11.007","article-title":"Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: a comparative cohort study","volume":"27","author":"Yao","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0595","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000538","article-title":"Anti-MOG encephalitis mimicking small vessel CNS vasculitis","volume":"6","author":"Patterson","year":"2019","journal-title":"Neurol - Neuroimmunol Neuroinflam"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0600","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bjophthalmol-2018-313142","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy","volume":"103","author":"Liu","year":"2019","journal-title":"Brit J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0605","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/rheumatology\/key282","article-title":"Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus","volume":"58","author":"Probstel","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103693_bb0610","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.msard.2018.10.003","article-title":"Atypical anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations","volume":"27","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0615","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.msard.2019.01.035","article-title":"Bilateral cingulate cortices lesions in two autoantibodies directed against MOG (MOG-Ab)-positive patients","volume":"29","author":"Kamada","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0620","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2019","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.autrev.2024.103693_bb0625","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","volume":"30","author":"Salama","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0630","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1120672118784797","article-title":"Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein","volume":"29","author":"Ducloyer","year":"2019","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0635","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.braindev.2019.02.011","article-title":"Clinical time course of pediatric acute disseminated encephalomyelitis","volume":"41","author":"Nishiyama","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.autrev.2024.103693_bb0640","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0645","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2024.103693_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116430","article-title":"Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: a Chinese cohort study","volume":"405","author":"Chen","year":"2019","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0655","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol - Neuroimmunol Neuroinflam"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0660","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb0665","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0670","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/1352458518761186","article-title":"Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis","volume":"25","author":"Hyun","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2024.103693_bb0675","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0680","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/dmcn.14114","article-title":"Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children","volume":"61","author":"Tantsis","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0685","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.braindev.2018.10.011","article-title":"MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: four cases and review of the literature","volume":"41","author":"Ikeda","year":"2019","journal-title":"Brain Dev"},{"issue":"AUG","key":"10.1016\/j.autrev.2024.103693_bb0690","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fneur.2019.00868","article-title":"Myelin oligodendrocyte glycoprotein (Mog) antibody diseases in children in central South China: clinical features, treatments, influencing factors, and outcomes","volume":"10","author":"Mao","year":"2019","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0695","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13791","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes","volume":"26","author":"Zhou","year":"2019","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0700","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12974-019-1521-5","article-title":"Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study","volume":"16","author":"Oertel","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"14","key":"10.1016\/j.autrev.2024.103693_bb0705","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1177\/1352458518811597","article-title":"Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis","volume":"25","author":"Oliveira","year":"2019","journal-title":"Mult Scler J"},{"issue":"12","key":"10.1016\/j.autrev.2024.103693_bb0710","first-page":"1381","article-title":"Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka","volume":"90","author":"Senanayake","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103693_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577078","article-title":"The clinical presentation and treatment of MOG antibody disease at a single academic center: a case series","volume":"337","author":"Brayo","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb0720","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2019.05.006","article-title":"The clinical spectrum of anti-MOG associated acquired demyelinating disorders: three case-reports","volume":"33","author":"Bellinvia","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2019.06.035","article-title":"The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"35","author":"Qin","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0730","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/WNO.0000000000000669","article-title":"Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"39","author":"Jelcic","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.autrev.2024.103693_bb0735","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"21","key":"10.1016\/j.autrev.2024.103693_bb0740","doi-asserted-by":"crossref","first-page":"e2924","DOI":"10.1212\/WNL.0000000000011030","article-title":"A clinico-neurophysiological study of urogenital dysfunction in MOG-antibody transverse myelitis","volume":"95","author":"Li","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103693_bb0745","article-title":"Age-related clinical presentation of MOG-IgG seropositivity in Israel","volume":"11","author":"Brill","year":"2020","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0750","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/WNO.0000000000001116","article-title":"Alterations in the retinal vascular network and structure in MOG antibody-associated disease: an optical coherence tomography angiography study","volume":"41","author":"Yu","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.autrev.2024.103693_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577143","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - a north Indian tertiary care Centre experience and review of literature","volume":"340","author":"Pedapati","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"31","key":"10.1016\/j.autrev.2024.103693_bb0760","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021238","article-title":"Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: a retrospective observational study","volume":"99","author":"Du","year":"2020","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb0765","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult Scler J"},{"issue":"12","key":"10.1016\/j.autrev.2024.103693_bb0770","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaophthalmol.2020.4231","article-title":"Assessment of pediatric optic neuritis visual acuity outcomes at 6 months","volume":"138","author":"Pineles","year":"2020","journal-title":"Jama Ophthalmol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0775","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0780","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fneur.2020.00089","article-title":"Case series: myelin oligodendrocyte glycoprotein-immunoglobulin G-related disease spectrum","volume":"11","author":"Alshamrani","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0785","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0790","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2024.103693_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102005","article-title":"Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood-brain barrier breakdown and peripheral plasmablasts","volume":"41","author":"Tanaka","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.593287","article-title":"Clinical and neuroimaging characteristics of pediatric acute disseminating encephalomyelitis with and without antibodies to myelin oligodendrocyte glycoprotein","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0805","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/0883073819877334","article-title":"Clinical features and outcomes of pediatric monophasic and recurrent idiopathic optic neuritis","volume":"35","author":"Jonzzon","year":"2020","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0810","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjophthalmol-2020-317524","article-title":"Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study","volume":"106","author":"Yang","year":"2022","journal-title":"Brit J Ophthalmol"},{"issue":"22","key":"10.1016\/j.autrev.2024.103693_bb0815","doi-asserted-by":"crossref","first-page":"e2302","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0820","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3988\/jcn.2020.16.3.461","article-title":"Clinical spectrum of myelin oligodendrocyte glycoprotein-immunoglobulin g-associated disease in Korean children","volume":"16","author":"Yoo","year":"2020","journal-title":"J Clin Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0825","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ene.14089","article-title":"Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients","volume":"27","author":"Shor","year":"2020","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0830","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116673","article-title":"Deciphering anti-MOG IgG antibodies: clinical and radiological spectrum, and comparison of antibody detection assays","volume":"410","author":"Tzartos","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103693_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577260","article-title":"Diagnostic features of initial demyelinating events associated with serum MOG-IgG","volume":"344","author":"Orlandi","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb0845","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2147\/OPTH.S271820","article-title":"Etiologies of acute optic neuritis in Thailand: an observational study of 171 patients","volume":"14","author":"Vanikieti","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0850","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1352458520939008","article-title":"Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder","volume":"27","author":"Cai","year":"2020","journal-title":"Mult Scler J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0855","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study","volume":"7","author":"Li","year":"2020","journal-title":"Neurol - Neuroimmunol Neuroinflam"},{"issue":"12","key":"10.1016\/j.autrev.2024.103693_bb0860","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G\u2013associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0865","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1007\/s00415-020-09755-x","article-title":"MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation","volume":"267","author":"Loos","year":"2020","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0870","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-019-09586-5","article-title":"MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity","volume":"267","author":"Papathanasiou","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0875","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody positive patients in a multi-ethnic Canadian cohort","volume":"11","author":"Cross","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0880","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4103\/0028-3886.294831","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated CNS demyelination: clinical spectrum and comparison with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder","volume":"68","author":"Ojha","year":"2020","journal-title":"Neurol India"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01658107.2019.1607883","article-title":"Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic Perineuritis","volume":"44","author":"Lopez-Chiriboga","year":"2020","journal-title":"Neuro-ophthalmology"},{"key":"10.1016\/j.autrev.2024.103693_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102376","article-title":"Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey","volume":"44","author":"Inan","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0895","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0900","first-page":"1","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in Canada","volume":"48","author":"Garg","year":"2020","journal-title":"Can J Neurol Sci J Can Des Sci Neurologiq"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0905","first-page":"653","article-title":"Neurological spectrum disorders associated with anti-mog antibody","volume":"20","author":"Mnaather","year":"2020","journal-title":"Medico-Legal Update"},{"key":"10.1016\/j.autrev.2024.103693_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101917","article-title":"Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients","volume":"39","author":"Giacomini","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb0915","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dmcn.14594","article-title":"Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes","volume":"62","author":"Deiva","year":"2020","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0920","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dmcn.14336","article-title":"Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease","volume":"62","author":"Albassam","year":"2020","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb0925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0930","first-page":"1","article-title":"Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-ab)-associated diseases: an Indian perspective","volume":"121","author":"Chaudhuri","year":"2020","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb0935","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb0940","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamaneurol.2020.0001","article-title":"Unilateral leptomeningeal enhancement in myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease","volume":"77","author":"Budhram","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0945","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000508070","article-title":"Unilateral optic neuritis in children: experience of a tertiary centre","volume":"83","author":"Armindo","year":"2020","journal-title":"Eur Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb0950","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0955","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1352458520937281","article-title":"Visual field loss and structure-function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody","volume":"27","author":"Deschamps","year":"2020","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2024.103693_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102874","article-title":"\u201cPeppering the pons\u201d: CLIPPERS or myelin oligodendrocyte glycoprotein associated disease?","volume":"51","author":"Obeidat","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb0965","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.braindev.2021.01.008","article-title":"A nation-wide survey of Japanese pediatric MOG antibody-associated diseases","volume":"43","author":"Azumagawa","year":"2021","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0970","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jnnp-2020-324422","article-title":"Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany","volume":"92","author":"Liu","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103693_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102718","article-title":"Anti-MOG associated disorder-clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience","volume":"48","author":"Rempe","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb0980","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10072-020-04892-7","article-title":"Anti-MOG-associated demyelinating disorders: two sides of the same coin","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb0985","article-title":"Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina","volume":"7","author":"Contentti","year":"2021","journal-title":"Multiple Sclerosis J- Exp Translat Clin"},{"issue":"7","key":"10.1016\/j.autrev.2024.103693_bb0990","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103693_bb0995","article-title":"Clinical and imaging features of patients with encephalitic symptoms and myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103693_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102837","article-title":"Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes","volume":"50","author":"Ferilli","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb1005","article-title":"Clinical and prognostic analysis of autoantibody-associated CNS demyelinating disorders in children in Southwest China","volume":"12","author":"Li","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.752557","article-title":"Clinical and radiological characteristics of children and adults with first-attack myelin oligodendrocyte glycoprotein antibody disease and analysis of risk factors for predicting the severity at disease onset in Central China","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1015","doi-asserted-by":"crossref","first-page":"14603","DOI":"10.1038\/s41598-021-93976-1","article-title":"Clinical characteristics of optic neuritis phenotypes in a 3-year follow-up Chinese cohort","volume":"11","author":"Feng","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103693_bb1020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2021.09.035","article-title":"Clinical characteristics, disease course, and outcomes of paediatric patients with myelin oligodendrocyte glycoprotein-ab associated disease: a retrospective clinical study","volume":"94","author":"Zhang","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13760-020-01499-9","article-title":"Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience","volume":"121","author":"Serin","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.autrev.2024.103693_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577742","article-title":"Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): a prospective observational study and review of literature","volume":"361","author":"Nagireddy","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"13","key":"10.1016\/j.autrev.2024.103693_bb1035","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103693_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577494","article-title":"Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders","volume":"353","author":"Du","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb1045","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb1050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28871","article-title":"Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes","volume":"4","author":"Fadda","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1055","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00415-020-10097-x","article-title":"Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis","volume":"268","author":"Vicini","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577456","article-title":"Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - a prospective study from Northwest India","volume":"351","author":"Choudhary","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/cns.13461","article-title":"Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort","volume":"27","author":"Veselaj","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2024.103693_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb1075","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held","year":"2021","journal-title":"Multiple Scler J Exp Transl Clin"},{"key":"10.1016\/j.autrev.2024.103693_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102965","article-title":"Modified models to distinguish central nervous system demyelinating diseases with brain lesions","volume":"52","author":"Chen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103229","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses","volume":"56","author":"Epstein","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/aian.AIAN_627_19","article-title":"Myelin oligodendrocyte glycoprotein (MOG)-IgG associated demyelinating disease: our experience with this distinct syndrome","volume":"24","author":"Pujari","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1095","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00415-020-10300-z","article-title":"Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder","volume":"268","author":"Netravathi","year":"2021","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1100","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ene.14654","article-title":"Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: a comparative study in Chinese Han patients","volume":"28","author":"ZhangBao","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103258","article-title":"Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study","volume":"56","author":"Santos","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120035","article-title":"Optic perineuritis: a Canadian case series and literature review","volume":"430","author":"Xie","year":"2021","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1115","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000924","article-title":"Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders","volume":"8","author":"Rinaldi","year":"2021","journal-title":"Neurol - Neuroimmunol Neuroinflam"},{"issue":"15","key":"10.1016\/j.autrev.2024.103693_bb1120","doi-asserted-by":"crossref","first-page":"e2006","DOI":"10.1212\/WNL.0000000000011744","article-title":"Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder","volume":"96","author":"Collongues","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103693_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577467","article-title":"Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders","volume":"351","author":"Akaishi","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103693_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102964","article-title":"Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: a new mimicker of progressive multiple sclerosis?","volume":"52","author":"Marcucci","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.03.006","article-title":"Prolonged fever -An atypical presentation in MOG antibody associated disorders","volume":"122","author":"Udani","year":"2021","journal-title":"Pediatr Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb1140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/08830738211025867","article-title":"Rate of leptomeningeal enhancement in pediatric myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis","volume":"36","author":"Gadde","year":"2021","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb1145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1352458520913970","article-title":"Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease","volume":"27","author":"Hyun","year":"2021","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2024.103693_bb1150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.seizure.2021.09.011","article-title":"Seizures in myelin oligodendrocyte glycoprotein antibody-associated disorders and related immune factors","volume":"92","author":"Liu","year":"2021","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb1155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1160","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673472","article-title":"Structural and functional alterations in visual pathway after optic neuritis in MOG antibody disease: a comparative study with AQP4 seropositive NMOSD","volume":"12","author":"Gao","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1165","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.679430","article-title":"The clinical, radiologic, and prognostic differences between pediatric and adult patients with myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis","volume":"12","author":"Xu","year":"2021","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb1170","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: an observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103017","article-title":"Two cases of myelin oligodendrocyte glycoprotein antibody-associated disease presenting with cauda Equina syndrome without conus myelitis","volume":"52","author":"Kang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb1185","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol - Neuroimmunol Neuroinflam"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb1190","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong","year":"2018","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb1195","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4\u2013IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1205","doi-asserted-by":"crossref","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb1210","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4103\/aian.AIAN_250_17","article-title":"Anti myelin oligodendrocyte glycoprotein associated immunoglobulin G (AntiMOG-IgG)-associated neuromyelitis optica spectrum disorder with persistent disease activity and residual cognitive impairment","volume":"20","author":"Pandit","year":"2017","journal-title":"Ann Indian Acad Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb1220","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/jnnp-2022-330901","article-title":"Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study","volume":"94","author":"ZhangBao","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1225","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody\u2013associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb1230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?","volume":"94","author":"Chen","year":"2023","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103693_bb1235","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2023-332851","article-title":"The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease","volume":"95","author":"Liyanage","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb1240","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/trf.17766","article-title":"Autoantibody profiles in intravenous immunoglobulin preparations: a possible cause of mistaken autoimmunity diagnosis","volume":"64","author":"Miyamoto","year":"2024","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1250","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/eji.200737557","article-title":"Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab","volume":"38","author":"Ferraro","year":"2008","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-Aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2012","journal-title":"J Clin Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103693_bb1260","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/13524585211011450","article-title":"Optic chiasm involvement in AQP-4 antibody\u2013positive NMO and MOG antibody\u2013associated disorder","volume":"28","author":"Tajfirouz","year":"2021","journal-title":"Mult Scler J"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb1270","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ene.15897","article-title":"Relevance of kappa free light chains index in patients with aquaporin-4 or myelin-oligodendrocyte-glycoprotein antibodies","volume":"30","author":"Deschamps","year":"2023","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb1275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/jnnp-2021-326779","article-title":"Frequency of MOG-IgG in cerebrospinal fluid versus serum","volume":"93","author":"Pace","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1280","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001095","article-title":"Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability","volume":"9","author":"Kwon","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb1285","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2024.103693_bb1290","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/acn3.52163","article-title":"The clinical relevance of MOG antibody testing in cerebrospinal fluid","volume":"11","author":"Reynolds","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1295","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/opo.13123","article-title":"Normative data for macular and retinal nerve fibre layer thickness in healthy German children and adolescents using optical coherence tomography","volume":"43","author":"S\u00f6hnel","year":"2023","journal-title":"Ophthalmic Physiol Opt"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1300","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WNO.0000000000001717","article-title":"Normative data and conversion equation for spectral-domain optical coherence tomography in an international healthy control cohort","volume":"42","author":"Kenney","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.autrev.2024.103693_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103525","article-title":"OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis RNFL thickening in acute optic neuritis from MOGAD vs MS","volume":"58","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb1310","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.26440","article-title":"Longitudinal retinal changes in MOGAD","volume":"92","author":"Oertel","year":"2022","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103693_bb1315","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1038\/s41598-022-19848-4","article-title":"Structure\u2013function correlates of vision loss in neuromyelitis optica spectrum disorders","volume":"12","author":"Gigengack","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103693_bb1320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejpn.2023.12.006","article-title":"Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"48","author":"Gericke","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103693_bb1325","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance Intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2024.103693_bb1330","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241239105","article-title":"Treatment access and satisfaction on disease-modifying therapies of neuromyelitis optica spectrum disorder patients in China: a cross-sectional survey","volume":"17","author":"Yu","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2024.103693_bb1335","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2019.05.013","article-title":"Neuromyelitis optica testing and treatment: availability and affordability in 60 countries","volume":"33","author":"Holroyd","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10.1016\/j.autrev.2024.103693_bb1340","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2024.103693_bb1345","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2024.103693_bb1350","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1355","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-IgG+ NMOSD","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"issue":"4","key":"10.1016\/j.autrev.2024.103693_bb1360","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s13760-022-01983-4","article-title":"Relapse of myelin oligodendrocyte glycoprotein antibody-associated demyelinating disease in an elderly patient after long-term remission","volume":"123","author":"Mayuzumi","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.autrev.2024.103693_bb1365","first-page":"1","article-title":"Rapid differentiation of MOGAD and MS after a single optic neuritis","author":"Pakeerathan","year":"2024","journal-title":"J Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T19:06:52Z","timestamp":1734462412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":273,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1568997224001848"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103693","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103693"}}